Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2007 1
2008 1
2009 2
2010 1
2011 2
2013 1
2014 2
2015 1
2016 1
2017 2
2018 1
2019 2
2020 1
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study.
De Laurentiis M, Caputo R, Mazza M, Mansutti M, Masetti R, Ballatore Z, Torrisi R, Michelotti A, Zambelli A, Ferro A, Generali D, Vici P, Coltelli L, Fabi A, Marchetti P, Ballestrero A, Spazzapan S, Frassoldati A, Sarobba MG, Grasso D, Zamagni C. De Laurentiis M, et al. Among authors: grasso d. Target Oncol. 2022 Nov;17(6):615-625. doi: 10.1007/s11523-022-00913-x. Epub 2022 Sep 24. Target Oncol. 2022. PMID: 36152144 Free PMC article. Clinical Trial.
Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2- Advanced Breast Cancer Patients: An Italian Managed Access Program.
Staropoli N, Geuna E, Rinaldi G, Bisagni G, Scotti V, Faggioni G, Vannini L, Arcara C, Moretti G, Gunnellini M, Coltelli L, Verderame F, Livi L, Sanna G, Grasso D, Abbinante G, Ragni F. Staropoli N, et al. Among authors: grasso d. Curr Oncol. 2022 Sep 17;29(9):6635-6641. doi: 10.3390/curroncol29090521. Curr Oncol. 2022. PMID: 36135090 Free PMC article.
Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 Trial.
Caputo R, Fabi A, Romagnoli E, Baldini E, Grasso D, Fenderico N, Michelotti A. Caputo R, et al. Among authors: grasso d. Breast Cancer (Dove Med Press). 2022 Oct 18;14:351-362. doi: 10.2147/BCTT.S376902. eCollection 2022. Breast Cancer (Dove Med Press). 2022. PMID: 36267663 Free PMC article.
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Bachelot T, et al. Ann Oncol. 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061. Ann Oncol. 2019. PMID: 30796821 Free article. Clinical Trial.
The institution of a Multi-disciplinary Italian Breast Unit: Reflections of the first psychosocial research study results on distress and quality of life.
Dionigi F, Milani R, Garcia-Etienne CA, Praticò V, Riboni G, Della Valle A, Ferrari A, Grasso D, Lasagna A, Pedrazzoli P, Klersy C, Politi P, Sgarella A, Manna S, Conti C. Dionigi F, et al. Among authors: grasso d. Breast J. 2019 Jul;25(4):678-681. doi: 10.1111/tbj.13244. Epub 2019 May 24. Breast J. 2019. PMID: 31127684
21 results